Independent
Tenure on this board
1.8 yrs
2 nominees · 3 ballot items.
Elect two Class III directors; approve an amendment to the Stock Incentive Plan to allow issuance of restricted stock units (RSUs); and an advisory (non-binding) vote to approve named executive officer compensation (say-on-pay).
Elect two Class III directors, Arun Nayar and Srinivas Kandula, to serve three-year terms expiring in 2029.
Approve an amendment to the Company's Stock Incentive Plan to authorize Restricted Stock Units (RSUs) as a form of award under the Plan.
This management proposal requests shareholder approval to amend the Company’s Stock Incentive Plan to add Restricted Stock Units (RSUs) as an authorized award type. Management frames the change as a necessary modernization of its equity program to align compensation practices with market norms and to enhance the Company’s ability to attract and retain key employees by expanding beyond stock options and restricted shares. The amendment is limited in scope — it solely authorizes RSUs and does not alter other Plan provisions — and will become effective only upon shareholder approval. Approving RSUs gives the Compensation Committee a flexible tool to deliver equity-based compensation that vests over time or upon performance, reducing immediate dilution risks while retaining retention value. The Board recommends FOR, citing alignment of employee and shareholder interests and competitive recruiting considerations; the Compensation Committee’s oversight and Plan administration provisions remain in place. Potential governance considerations include incremental dilution, tax and accounting treatment of RSUs compared with options, and any impact on existing equity run-rate metrics; the proxy discloses authorized share counts and historical grants to contextualize availability. For activist or institutional investors, key evaluation points will be whether the Company discloses anticipated usage, target recipients, typical vesting/performance conditions, and whether RSU grants will preserve or alter the pay-for-performance profile. If approved, RSUs would broaden the Company’s compensation toolkit, but shareholders should monitor subsequent grant practices and disclosure to ensure alignment with long-term shareholder value creation.
A non-binding, advisory vote to approve the compensation of the Company's named executive officers as disclosed in the proxy statement.
This advisory (non-binding) management proposal asks shareholders to approve the overall compensation of the named executive officers as disclosed in the proxy. Management positions the vote as an annual 'say-on-pay' designed to solicit shareholder feedback on the Company’s pay practices rather than approve specific awards; the Board has committed to consider the vote outcome when evaluating compensation policies. The company emphasizes a pay-for-performance philosophy, combining base salary, annual performance cash bonuses, and equity awards (options and performance-based awards) to align executive incentives with long-term shareholder value. The Compensation Committee administers the program and retains discretion to structure awards and to adjust metrics; the proxy discloses material components, benchmarking practices, and governance safeguards including clawback and Section 162(m)/409A compliance. Because the vote is advisory, a negative result does not automatically change awards but typically triggers shareholder engagement and potential adjustments; the company explicitly commits to consider significant dissent. Investors evaluating this proposal should weigh the disclosed pay metrics, the linkage between pay and performance (including the performance objectives and realized payouts), the degree of equity-based 'at-risk' pay, severance and change-in-control provisions, and recent say-on-pay outcomes. A FOR vote supports current compensation philosophy and continuity of management's approach; a vote AGAINST signals shareholder concern and usually prompts follow-up dialogue with the Compensation Committee.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | CAPITAL MANAGEMENT CORP /VA | 7.98% | 956,894 | $5M |
| 2 | DIMENSIONAL FUND ADVISORS LP | 1.68% | 202,030 | $1M |
| 3 | ENVESTNET ASSET MANAGEMENT INC | 1.36% | 163,028 | $928K |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 1.22% | 146,514 | $834K |
| 5 | RENAISSANCE TECHNOLOGIES LLC | 0.85% | 102,427 | $583K |
| 6 | Indivisible Partners | 0.70% | 83,928 | $478K |
| 7 | Advyzon Investment Management, LLC | 0.68% | 81,538 | $464K |
| 8 | BlackRock, Inc. | 0.58% | 69,543 | $396K |
| 9 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.39% | 47,141 | $268K |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 0.30% | 36,016 | $205K |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.